Inside The PTAB's Seagen Cancer Drug Patent Decision
By Ryan Hagglund · February 23, 2024, 6:20 PM EST
The latest chapter in the complex and multifaceted Daiichi Sankyo Inc. v. Seagen Inc.[1] patent dispute — concerning antibody-drug conjugate technology, or ADC, and pitting Seagen against Daiichi and its collaborator, AstraZeneca...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login